BiondVax moves to new facility for production of universal flu vaccine



JERUSALEM, August 20, 2018 / PRNewswire / – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal flu vaccine candidate, today reported the relocation of the company to a newly built medium-sized commercial production facility in Jerusalem, Israel.

Dr. Shimon Hassin, The COO of BiondVax, said:The new BiondVax facility is tailor-made for GMP production of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide comprehensive protection against influenza. While BiondVax enters this next exciting phase, I want to thank our partners at Biopharmax for the design and construction of our new facility. "

Located in the Jerusalem Bio Park, a biotech hub at the Hadassah Medical Center Hebrew university Ein Kerem campus, the new approximately 20,000 square feet (1850m2) facility includes offices, laboratories and GMP production suites with a potential annual capacity of 40 million doses of M-001 in bulk with up to 20 million injections with one dose.

The contact details of BiondVax, including telephone, fax, e-mail and postal address, are currently the same as before the move.

About BiondVax Pharmaceuticals Ltd.

BiondVax is a Phase 3 clinical biopharmaceutical company that develops a universal flu vaccine. The candidate vaccine, called M-001, is designed to provide more seasonal protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology uses a unique combination of conserved and common influenza virus peptides, which activate both arms of the immune system for cross protection and long-lasting effects. In a total of 6 completed phase 1/2 and phase 2 clinical trials in humans, with 698 participants, the vaccine has been shown to be safe, well-tolerated and immunogenic. BiondVax is traded on NASDAQ: BVXV. Go to www.biondvax.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect", "believe", "intend", "plan", "continue", "may", "will," " anticipation "and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties that reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could lead to results are significantly different from those expected by the management of BiondVax Pharmaceuticals Ltd. Risk & # 39; s and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any follow-up tests; timing of receipt of the legal approval of the new production facility of its products; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk of drug development being accompanied by a lengthy and expensive process with an uncertain outcome; the ability of the company to retain, retain and defend its intellectual property and patents; whether our vaccine candidate will go through the trial of the clinical trial in time or not and receive approval from the US Food and Drug Administration or equivalent foreign regulatory authorities; the adequacy of available cash and the ability to raise capital when needed. More detailed information on the company's risks and uncertainties can be found under the heading "Risk factors" in our annual report on Form 20-F for the year ended. 31 December 2017 filed with the US Securities and Exchange Commission, or SEC, which is available on the SEC website, www.sec.gov, and in the company's periodic filings with the SEC and the Tel-Aviv Stock Exchange. We undertake no obligation whatsoever to revise or update a forward-looking statement for any reason whatsoever.

For more information, please contact:

BiondVax
Joshua Phillipson
+ 972-8-930-2529
[email protected]

Cision View original content: http: //www.prnewswire.com/news-releases/biondvax-moves-to-new-universal-flu-vaccine-manufacturing-facility-300699267.html

SOURCE BiondVax Pharmaceuticals Ltd.


Source link

Leave a Reply